A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus (ALE09)

Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus (ALE09)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Ajulemic acid (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Oct 2017.
    • 01 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Sep 2017.
    • 09 Aug 2017 According to a Corbus Pharmaceuticals media release, the study will begin in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top